LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to “Strong-Buy”

Turn Therapeutics (NASDAQ:TTRX) was upgraded by equities research analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Turn Therapeutics to a “hold” rating in a research report on Saturday. D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 target price on shares of Turn Therapeutics in a research report on Tuesday, March 24th. Finally, Weiss Ratings upgraded Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Turn Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Turn Therapeutics Trading Up 1.3%

TTRX stock opened at $10.18 on Monday. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The stock has a market cap of $303.26 million and a price-to-earnings ratio of -53.58. The company has a fifty day moving average price of $6.59 and a two-hundred day moving average price of $4.77. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of Turn Therapeutics

A number of institutional investors have recently bought and sold shares of the business. RVW Wealth LLC bought a new position in shares of Turn Therapeutics during the fourth quarter worth approximately $71,000. Composition Wealth LLC bought a new position in Turn Therapeutics in the 4th quarter valued at about $63,000. HighTower Advisors LLC acquired a new position in shares of Turn Therapeutics in the 4th quarter valued at approximately $78,000. Wellington Shields & Co. LLC acquired a new position in shares of Turn Therapeutics in the 4th quarter valued at approximately $259,000. Finally, Geode Capital Management LLC bought a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.